KAO JOHN E sold $4.1M of ALHC (indirect holdings)

Alignment Healthcare and executives filed to dismiss a whistleblower suit by former exec Hakan Kardes, who alleges earnings were artificially boosted for higher bonuses. The company claims Kardes resigned voluntarily and his claims are false. Kardes says he was forced out after reporting accounting irregularities, affecting EBITDA and executive bonuses. Shares dropped initially but rebounded.

Kaplan Fox & Kilsheimer LLP said it is investigating potential securities violations at Alignment Healthcare, Inc. (NASDAQ: ALHC) after a whistleblower complaint alleging accounting irregularities that allegedly inflated previously reported and projected results. The complaint cites operating expenses allegedly misclassified as capital expenditures, affecting Adjusted EBITDA. On July 8, 2026, ALHC shares fell $4.02, or 16.7%, to close at $20.03.

Alignment Healthcare, a Medicare Advantage insurer, secured a $200 million credit line from Citibank on Feb. 26, 2026, running three years for permitted acquisitions. As of June 30, 2026, it had not drawn on the facility. In a July 30, 2026 SEC filing, it said it expects to acquire provider groups and Medicare Advantage plans. Alignment operates in 45 markets with 294,100 members.

Alignment Healthcare (ALHC) reported Q2 EPS of 17 cents, up from 7 cents a year earlier, with revenue rising 31.6% to $1.34B and beating consensus. Membership reached about 294,100. The company raised 2026 guidance to $5.195B-$5.225B revenue and 298,000-301,000 membership, but expects lower Q3 adjusted EBITDA ($20M-$30M) due to added clinical, AI and expansion spending.

Kaplan Fox said a former Alignment Healthcare executive filed a whistleblower complaint alleging accounting irregularities that allegedly inflated reported and projected results, including Adjusted EBITDA, and misclassified operating expenses as capital expenditures. After the July 8, 2026 report, ALHC shares fell $4.02, or 16.7%, to close at $20.03, according to the article.

Alignment Healthcare (ALHC) shares fell 14.8% after the company said it will reinvest profits, lowering expected second-half 2026 earnings. On its Q2 2026 call, management raised full-year revenue guidance but expects only about 30% of adjusted EBITDA in the second half, versus 40% a year earlier, due to investment timing.